Skip to content

Study · Animal study (in vivo) · rat · 2020

2 results

Lipopolysaccharides transport during fat absorption in rodent small intestine.

Akiba Y, Maruta K, Takajo T, Narimatsu K, Said H, Kato I, Kuwahara A, Kaunitz JD

American journal of physiology. Gastrointestinal and liver physiology11 May 2020Cited by 53 (Europe PMC)

PMID32390462 (opens in a new tab)PMCIDPMC7311662 (opens in a new tab)DOI10.1152/ajpgi.00079.2020 (opens in a new tab)PepBankPUB-32390462
Source linkPubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats during fat absorption, intravenous teduglutide acutely inhibited FITC-LPS transport into the portal vein.

    In plain wordsIn rats during fat absorption, intravenous teduglutide reduced FITC-LPS transport into the portal vein.

    Peptide
    Teduglutide
    Outcome
    DecreaseFITC-LPS transport into portal vein
    Study

    ratn: not reported in source

    Anesthetized rats during FITC-LPS and OA/TCA perfusion
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    Intraveous injection of the stable GLP-2 analog teduglutide acutely inhibited FITC-LPS transport into the PV, yet accelerated FITC-LPS transport into the lymph via Nω-nitro-l-arginine methyl ester (l-NAME)- and PG97-269-sensitive mechanisms.
    1 context sentence
    Summary · context
    In anesthetized rats, the appearance of fluorescein isothiocyanate (FITC)-LPS into the portal vein (PV) and the mesenteric lymph was simultaneously monitored after intraduodenal perfusion of FITC-LPS with oleic acid and taurocholate (OA/TCA).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats during fat absorption, intravenous teduglutide accelerated FITC-LPS transport into lymph.

    In plain wordsIn rats during fat absorption, intravenous teduglutide increased FITC-LPS transport into lymph.

    Peptide
    Teduglutide
    Outcome
    IncreaseFITC-LPS transport into lymph
    Study

    ratn: not reported in source

    Anesthetized rats during FITC-LPS and OA/TCA perfusion
    Outcome group
    Gastrointestinal protection · Gastrointestinal
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    Intraveous injection of the stable GLP-2 analog teduglutide acutely inhibited FITC-LPS transport into the PV, yet accelerated FITC-LPS transport into the lymph via Nω-nitro-l-arginine methyl ester (l-NAME)- and PG97-269-sensitive mechanisms.
    1 context sentence
    Summary · context
    In anesthetized rats, the appearance of fluorescein isothiocyanate (FITC)-LPS into the portal vein (PV) and the mesenteric lymph was simultaneously monitored after intraduodenal perfusion of FITC-LPS with oleic acid and taurocholate (OA/TCA).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.